Microbiology Testing for Cardiovascular Devices
Cardiovascular devices face the strictest sterility, endotoxin, and residuals thresholds in the device industry. Boulder BioLabs supports cardiovascular device manufacturers through validation, routine release, and post-market monitoring — co-located with Boulder Sterilization's EO and CD cycles.
Tests This Industry Requires
- Sterility Testing
- LAL / Endotoxin Testing
- EO Residuals Testing
- Bioburden Testing
- Method Suitability (B/F)
What Makes Cardiovascular Testing Different
Cardiovascular devices typically have complex internal geometries (lumens, braided structures, coatings) that challenge both extraction recovery (for bioburden) and aseptic technique (for sterility). Method suitability becomes more critical, not less.
Validation Pathway
For new cardiovascular device introductions, our typical scope is: bioburden recovery efficiency study → method suitability → sterility validation (half-cycle, full-cycle, PCD) → EO residuals validation → BET inhibition/enhancement → routine release program. Most of this can be bundled into a single integrated quote with Boulder Sterilization.